GSK PLC has issued a statement asserting that scientific consensus indicates no consistent or reliable evidence that ranitidine, the active ingredient in its discontinued heartburn drug Zantac, increases the risk of any cancer. This follows the announcement that a woman who claimed Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday. Additionally, GSK and other drugmakers have asked a Delaware court for permission to appeal a ruling that allows more than 70,000 lawsuits claiming Zantac causes cancer to proceed.
GSK and other drugmakers on Monday asked a Delaware court for permission to appeal a ruling allowing more than 70,000 lawsuits claiming that heartburn drug Zantac causes cancer to go forward. https://t.co/JZdEVK70gs https://t.co/JZdEVK70gs
Chemical and manufacturing groups sued the U.S. government over a landmark drinking-water standard that would require cleanup of "forever chemicals" linked to cancer and other health risks. https://t.co/t2KG651w19
A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced. https://t.co/wIi7vglAsh https://t.co/wIi7vglAsh
A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court, the company announced https://t.co/mXqheAyfos https://t.co/JyBhN7tTaU
GSK PLC - STATEMENT: ZANTAC (RANITIDINE) LITIGATION GSK - SCIENTIFIC CONSENSUS IS THAT THERE IS NO CONSISTENT OR RELIABLE EVIDENCE THAT RANITIDINE INCREASES RISK OF ANY CANCER